August 13, 2019
According to the American Cancer Society, triple negative breast cancer (TNBC) accounts for approximately 10-15% of all breast cancer. What is TNBC? How is it different from other forms of breast cancer? Stephanie Graff, MD, Director of the Breast Cancer Program at Sarah Cannon Cancer Institute at HCA Midwest Health and Associate Director of the […]
October 17, 2018
Erika Hamilton, MD, Director of the Breast Cancer and Gynecologic Cancer Research Program at Sarah Cannon, shares the exciting advancements in the research and treatment of triple negative breast cancer. “There have been several exciting developments in breast cancer research, including promising data for immunotherapy and targeted treatments for patients with triple negative breast cancer,” […]